

# Medical Journal of Indonesia

- ✓ Editorial
- ✓ Maneuver for nasogastric tube insertion
- ✓ Radial extracorporeal shockwave therapy
- ✓ Safety of Td vaccine in pregnancy
- ✓ Chronic peritoneal dialysis in children
- ✓ Microscopic test for fat malabsorption
- ✓ Constipation questionnaire validation
- ✓ Detection of *Mycobacterium leprae*
- ✓ Universal health coverage for geriatrics
- ✓ Anthropometric risk of femoral fracture
- ✓ HLA-Cw6 and psoriasis in Javanese ethnic
- ✓ Hemodialysis patients with hepatitis C
- ✓ Internet addiction in residents' perspective
- ✓ Heterotopic ossification in a child
- ✓ Rationale of radioimmunotherapy
- ✓ Congenital hypothyroidism on IQ and QoL



<http://mji.ui.ac.id>

Published by the Faculty of Medicine Universitas Indonesia  
Official Scientific Journal of the Faculty of Medicine Universitas Indonesia  
in collaboration with German-Indonesia Medical Association (DIGH)  
Jl. Salemba Raya No. 6 Jakarta 10430  
Telp. +62-21-29189160 ext. 201605



# Medical Journal of Indonesia

The **Medical Journal of Indonesia** (abbr: Med J Indones) was founded in 1991 as the Medical Journal of the University of Indonesia (abbr: Med J Univ Indon). It has been published quarterly consistently and continuously since 1992, covering a wide range of medical subject and issues from every medical specialist aspect. In 1995 the name was changed to Medical Journal of Indonesia which reflected the widening of its coverage beyond. Started from 2011, Deutsch-Indonesische Gesellschaft für Medizin (DIGM) Medical Journal has been merged to Medical Journal of Indonesia. This also means Medical Journal of Indonesia is officially collaborated with DIGM and Faculty of Medicine Universitas Indonesia as the publisher.

## Focus and Scope

Medical Journal of Indonesia focuses on promoting medical sciences generated from **basic sciences**, **clinical**, and **community** or public health research to integrate researches in all aspects of human health.

This journal publishes **original articles**, **reviews**, and also interesting **case reports**.

**Brief communications** containing short features of medicine, latest developments in diagnostic procedures, treatment, or other health issues that is important for the development of health care system are also acceptable.

**Letters and commentaries** of our published articles are welcome.

## Abstracting and Indexing

ACI; BASE; CAB Abstracts; CiteFactor; CNKI; Dimensions; DOAJ; EBSCO; Electronic Journals Library; Embase; ESCI; GARUDA; Global Health; Google Scholar; Hinari; IMSEAR; ISC; JournalTOCs; Microsoft Academics; PKP Index; Proquest; Scilit; Scopus; SINTA; Ulrichsweb Global Serial Directory; WorldCat.

## Open Access Policy

This journal is an open access journal which provides immediate, worldwide, barrier-free access to the full text of all published articles without charge readers or their institutions for access. Readers have right to read, download, copy, distribute, print, search, or link to the full texts of all articles in Medical Journal of Indonesia.

## Subscription

The printed issue should be subscribed for a full calendar year. The price per volume (four printed issues): international USD 160 (surface postage included), for ASEAN countries USD 100 (surface postage included), for Indonesia IDR 400,000 (surface postage excluded). This journal is published quarterly.

## Advertising Policy

Editorial materials will not be influenced by advertisement. Readers can criticize the advertisement by sending it to the office. Advertisement will appear in the print or online version depending on request. For all inquiries, contact the Medical Journal of Indonesia editorial office at Medical Journal of Indonesia, Education Tower 6th floor IMERI building, Faculty of Medicine Universitas Indonesia, Jalan Salemba Raya 6, Jakarta Pusat 10430, Indonesia; tel: +6221-29189160 ext. 201605; e-mail: mji@ui.ac.id.

## Copyright Notice

Faculty of Medicine Universitas Indonesia as publisher reserves the right of first publication of all published material and licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>). All statements in articles are the responsibility of the authors.

### Editorial Office

**Medical Journal of Indonesia**  
Jl. Salemba Raya 6, Jakarta Pusat 10430,  
Indonesia  
Tel: +6221-29189160 ext. 201605  
Mobile: +628111400115  
E-mail: mji@ui.ac.id

### Published by

**Faculty of Medicine Universitas Indonesia**  
Jl. Salemba Raya 6, Jakarta Pusat 10430,  
Indonesia  
Tel/fax: +62 21-3912477  
E-mail: humas@fk.ui.ac.id

### Printed by

**Warna Agung**  
Jl. Kalibaru Barat Raya 5a–5b, Kemayoran,  
Jakarta Pusat 10630 10460, Indonesia  
Tel: +62 21-42884708

Official Scientific Journal of the Faculty of Medicine, Universitas Indonesia  
in Collaboration with German-Indonesian Medical Association (DIGM)

Accredited (2016-2020) by the Directorate General of Research and Development Strengthening of the Ministry of Research, Technology and Higher Education of the Republic of Indonesia (No:21/E/KPT/2018).

∞ The paper meets the requirements of ISO 9706-1994 and ANSI/NISO z39.48-1992 (Permanence of Paper).

# Editorial Board

---

**Editor-in-chief** **Agus Rizal A.H. Hamid**  
Indonesia

**Editor-in-chief Emeritus** **Isnani A.S. Suryono**  
Indonesia

**Deputy Editor-in-chief** **Nafrialdi**  
Indonesia

**Business Manager** **Jose R.L. Batubara**  
Indonesia

**Managing Editor** **Felix F. Widjaja**  
Indonesia

---

## Editorial Board Members

**Agnes Kurniawan**  
Indonesia

**Bambang B. Siswanto**  
Indonesia

**David H. Garabrant**  
USA

**Farrokh Habibzadeh**  
Iran

**Grace Wangge**  
Indonesia

**Hak Hotta**  
Japan

**Hans-Joachim Freisleben**  
Germany

**Hans-Jürgen Mägert**  
Germany

**Harrina E. Rahardjo**  
Indonesia

**Inge Sutanto**  
Indonesia

**Jeanne A. Pawitan**  
Indonesia

**Jörg Haier**  
Germany

**Knut Adermann**  
Germany

**Laurentius A. Pramono**  
Indonesia

**Markus Meyer**  
Germany

**Melva Louisa**  
Indonesia

**Nia Kurniati**  
Indonesia

**Pradana Soewondo**  
Indonesia

**Rianto Setiabudy**  
Indonesia

**Saleha Sungkar**  
Indonesia

**Sentot Santoso**  
Germany

**Sri W.A. Jusman**  
Indonesia

**Theddeus O.H. Prasetyono**  
Indonesia

**Vivian Soetikno**  
Indonesia

**Wilfred C.G Peh**  
Singapore

---

## Associate Editors

**Apriani Oendari**  
USA

**Ary I. Savitri**  
Indonesia

**Hariyono Winarto**  
Indonesia

**Aulia Rizka**  
Indonesia

## Assistant Editors

**Dania Clarisa**  
Indonesia

**Lazuardi Gayu Ilhami**  
Indonesia

**Silvi Anastasia**  
Indonesia

**Debby Aditya**  
Indonesia

**Nikita Esther Lengkey**  
Indonesia

**Windu C. H. Notonagoro**  
Indonesia

**Novi A. Anggraeni**  
Indonesia

---

## Layout Editors

**Ilham Afriansyah**  
Indonesia

**Tsania Faza**  
Indonesia

## Production Editor

**Maytias Tri Pratiwi**  
Indonesia

# Medical Journal of Indonesia

Volume 28 • Number 4 • December 2019 • page 309–404 • pISSN: 0853-1773 • eISSN: 2252-8083

## Contents

### Editorial

- 309 How important is early detection and prompt treatment in congenital hypothyroidism patients?  
*Vivian Soetikno*

### Clinical Research

- 311 A randomized clinical trial of nasogastric tube insertion in intubated patient: comparison between finger method and reverse Sellick maneuver  
*Rahendra, Aida Rosita Tantri, Liliana Mangkuwerdojo*
- 316 Radial extracorporeal shockwave therapy on calcaneal spurs: a randomized controlled trial  
*Desy Kurniawati Tandiyo, Ratna Darjanti Haryadi, Ari Probandari, Didik Gunawan Tamtomo*
- 322 Safety profile of Td vaccination in Indonesian pregnant women: a post-marketing surveillance study  
*Hindra Irawan Satari, Mita Puspita, Julitasari Sundoro, Andrijono, Syafriyal, Rini Mulia Sari, Novilia Sjafri Bachtiar, Sri Rezeki Hadinegoro*
- 329 Five-year experience of continuous ambulatory peritoneal dialysis in children: a single center experience in a developing country  
*Cahyani Gita Ambarsari, Partini Pudjiastuti Trihono, Agustina Kadaristiana, Taralan Tambunan, Lily Mushahar, Henny Adriani Puspitasari, Eka Laksmi Hidayati, Sudung Oloan Pardede*
- 338 Effectivity of microscopic test as a simple diagnostic method to detect fat malabsorption in children  
*Ariani Dewi Widodo, Muzal Kadim, Ina Susianti Timan, Nuraini Irma Susanti, Fatima Safira Alatas, Agus Firmansyah*
- 345 Patient assessment of constipation quality of life questionnaire: validity and reliability for Indonesian population  
*Murdani Abdullah, Hasan Maulahela, Amanda Pitarini Utari, Pratiwi Dyah Kusumo, Amin Soebandrio, Ibrahim Achmad, Andy William, Dadang Makmun*
- 351 Detection of *Mycobacterium leprae* using real-time PCR in paucibacillary leprosy patients with negative acid-fast bacilli smears  
*Arleen Devita, Fera Ibrahim, Sri Linuwih Suseptyo Wardhani Menaldi, Angky Budianti, Andi Yasmon*
- 358 The functional status, rehospitalization, and hospital cost reduction in geriatric patients after the implementation of the universal health coverage program in the national referral hospital Indonesia  
*Czeresna Heriawan Soejono, Hari Sutanto*
- 365 Anthropometric measurements associated with intertrochanteric fractures in the elderly: a case-control study  
*Andy Ardiansyah, Sugeng Yuwana*

- 370 Association between HLA-Cw6 allele expression and characteristics of Javanese ethnic psoriasis patients in Indonesia  
*Thianti Sylviningrum, Ismiralda Oke Putranti, Octavia Permata Sari, Fitrantri Arjadi, Ermadi Satriyo Sudibyo, Siti Nurmala Manik*
- 375 Liver fibrosis of hepatitis C virus infection in routine hemodialysis patients in Indonesia  
*Aida Lydia, Anindia Larasati, Rino Alvani Gani, Ikhwan Rinaldi*

### Community Research

- 380 Perception of internet addiction among psychiatric residents in an urban area in Indonesia  
*Enjeline Hanafi, Kristiana Siste, Andreas Kurniawan, Martina Wiwie Setiawan Nasrun, Irmia Kusumadewi*

### Case Report

- 386 A case of extensive symptomatic lower limb heterotopic ossification in a boy  
*Inez Kartika, Elysanti Dwi Martadiani, I Gede Eka Wiratnaya, I Wayan Juli Sumadi*

### Review Article

- 391 The future of radiotherapy and immunotherapy concomitantly in cancer management  
*Sri Mutya Sekarutami, Handoko*

### Brief Communication

- 396 Effect of delayed diagnosis and treatment of congenital hypothyroidism on intelligence and quality of life: an observational study  
*Aman Bhakti Pulungan, Myrte Everarda Oldenkamp, Adrianus Sarinus Paulus van Trotsenburg, Wiwik Windarti, Hartono Gunardi*
- 402 Acknowledgment of Reviewers
- i Index Medical Journal of Indonesia Volume 28, January–December 2019

**Front Page:** Histopathological and radiological examinations confirming heterotopic ossification as reported by Kartika et al, these are published in this issue.

# Contents

---

**See the journal website for contents.**

# Index Medical Journal of Indonesia

Volume 28, January–December 2019

---

## **Author Index**

- |                    |            |                     |             |
|--------------------|------------|---------------------|-------------|
| Abdullah I.....    | (4):345–50 | Fathan H.....       | (1):21–7    |
| Abdullah M .....   | (3):241–5  | Firmansyah A .....  | (2):154–61  |
| Achmad I.....      | (4):345–50 | Firmansyah A .....  | (4):338–44  |
| Adeline.....       | (3):276–9  | Fitri A.....        | (3):241–5   |
| Adnani H .....     | (2):174–82 | Freisleben HJ ..... | (3):205–6   |
| Ahmad N .....      | (3):252–7  | Gani RA .....       | (4):375–9   |
| Ahmad S.....       | (3):252–7  | Gracia A.....       | (3):258–67  |
| Ahmed A.....       | (3):252–7  | Gunardi H .....     | (4):396–401 |
| Akram R .....      | (3):252–7  | Hadinegoro SR ..... | (4):322–8   |
| Alatas FS .....    | (4):338–44 | Hamid ARAH .....    | (1):1–2     |
| Alaydrus LL .....  | (2):162–6  | Hanafi E.....       | (4):380–5   |
| Ambarsari CG ..... | (4):329–37 | Hanaphi NABM .....  | (2):162–6   |
| Andrijono .....    | (1):63–9   | Handoko .....       | (4):391–5   |
| Andrijono .....    | (4):322–8  | Haniffah NABM.....  | (2):162–6   |
| Ardiansyah A.....  | (4):365–9  | Hanim D .....       | (2):174–82  |
| Ariani MD .....    | (2):116–22 | Harahap AR.....     | (1):63–9    |
| Arianti A.....     | (3):215–22 | Hardian .....       | (2):116–22  |
| Arjadi F .....     | (4):370–4  | Harumsari S .....   | (2):116–22  |
| Arodes ES.....     | (2):103–9  | Haryadi RD .....    | (4):316–21  |
| Artini W .....     | (3):258–67 | Hermawan G.....     | (2):129–33  |
| Ashari S .....     | (2):183–7  | Hestiantoro A ..... | (1):40–6    |
| Assandi P.....     | (1):82–91  | Hidayati EL.....    | (4):329–37  |
| Astuti BPK.....    | (1):40–6   | Horiyanto H .....   | (3):276–9   |
| Aziz A .....       | (3):252–7  | Ibrahim F.....      | (4):351–7   |
| Aziz SAA.....      | (3):300–8  | Ibrahim N .....     | (1):40–6    |
| Bachtiar NS .....  | (4):322–8  | Ibrahim N .....     | (3):300–8   |
| Baginda IS .....   | (3):241–5  | Irwinda R.....      | (1):57–62   |
| Bani AP.....       | (3):258–67 | Iskandar WJ .....   | (1):70–6    |
| Bardosono S .....  | (2):154–61 | Ismail RI .....     | (1):82–91   |
| Bariroh T .....    | (3):223–7  | Jasirwan SO .....   | (1):40–6    |
| Basiri B .....     | (1):28–34  | Javed S .....       | (3):252–7   |
| Budianti A .....   | (4):351–7  | Jeo WS .....        | (1):8–13    |
| Chaw L .....       | (2):162–6  | July J.....         | (3):276–9   |
| Cholil AR.....     | (1):47–56  | Juniarto AZ .....   | (2):116–22  |
| Delpisheh A.....   | (1):35–9   | Jusman SWA.....     | (1):14–20   |
| Devita A.....      | (4):351–7  | Kadaristiana A..... | (4):329–37  |
| Dewi BE.....       | (2):103–9  | Kadim M.....        | (4):338–44  |
| Djawas FA .....    | (3):228–33 | Kanoko M .....      | (1):63–9    |
| Effendi E.....     | (1):21–7   | Kartiika I.....     | (4):386–90  |
| Faradz SMH .....   | (2):116–22 | Kartinah NT .....   | (3):223–7   |

- Kartinah NT ..... (3):228–33  
 Kato M ..... (2):110–5  
 Kekalih A ..... (2):141–5  
 Kekalih A ..... (3):258–67  
 Kodariah R ..... (3):228–33  
 Koento T ..... (3):246–51  
 Kumala P ..... (1):47–56  
 Kurniasanti KS ..... (1):82–91  
 Kurniawan A ..... (4):380–5  
 Kusuma F ..... (2):141–5  
 Kusumadewi I ..... (4):380–5  
 Kusumajaya C ..... (3):280–3  
 Kusumaningrum N ..... (1):77–81  
 Kusumawati NRD ..... (2):123–8  
 Kusumo PD ..... (4):345–50  
 Laksmi LI ..... (1):3–7  
 Larasati A ..... (4):375–9  
 Larasati R ..... (3):284–91  
 Lindarto D ..... (1):47–56  
 Ling LJ ..... (3):300–8  
 Listyasari NA ..... (2):116–22  
 Louisa M ..... (2):110–5  
 Louisa M ..... (3):292–9  
 Lydia A ..... (4):375–9  
 Makmun D ..... (4):345–50  
 Mangkuwerdojo L ..... (4):311–5  
 Manik SN ..... (4):370–4  
 Marimpan ON ..... (3):246–51  
 Marsetio AF ..... (1):92–7  
 Martadiani ED ..... (4):386–90  
 Masthura A ..... (3):241–5  
 Maududi MS ..... (2):123–8  
 Maulahela H ..... (4):345–50  
 Melinda TF ..... (2):167–73  
 Menaldi SLSW ..... (4):351–7  
 Mexitalia M ..... (2):123–8  
 Mihardja H ..... (3):241–5  
 Moenadjat Y ..... (1):8–13  
 Moghadam AD ..... (1):35–9  
 Mohamadian F ..... (1):35–9  
 Muljadi R ..... (3):276–9  
 Mulyadi R ..... (2):134–40  
 Mushahar L ..... (4):329–37  
 Mustofa MS ..... (3):207–14  
 Naing L ..... (2):162–6  
 Nasrun MWS ..... (1):82–91  
 Nasrun MWS ..... (4):380–5  
 Nembo LF ..... (1):57–62  
 Nordin AJ ..... (3):300–8  
 Nugroho SW ..... (2):134–40  
 Nugroho SW ..... (2):183–7  
 Nuranna L ..... (1):63–9  
 Nuruddin A ..... (3):300–8  
 Oktariana VD ..... (3):258–67  
 Oldenkamp ME ..... (4):396–401  
 Pandhita BAW ..... (3):292–9  
 Pardede SO ..... (4):329–37  
 Pelupessy NU ..... (1):63–9  
 Pemayun TGD ..... (1):47–56  
 Perdamaian TK ..... (2):188–95  
 Prasetyo D ..... (2):154–61  
 Pribadi PM ..... (1):92–7  
 Prihadi JC ..... (3):280–3  
 Prihartono J ..... (2):134–40  
 Prijanti AR ..... (2):141–5  
 Probandari A ..... (4):316–21  
 Pujianto DA ..... (3):207–14  
 Pulungan AB ..... (4):396–401  
 Purnamawati S ..... (1):77–81  
 Puspita M ..... (4):322–8  
 Puspitasari HA ..... (4):329–37  
 Puteri HHS ..... (1):47–56  
 Puteri MU ..... (2):110–5  
 Putranti IO ..... (4):370–4  
 Rahardjo HE ..... (2):146–53  
 Rahardjo HE ..... (3):268–75  
 Rahendra ..... (4):311–5  
 Rahmati S ..... (1):35–9  
 Rahmi DNI ..... (3):292–9  
 Rahyussalim AJ ..... (1):92–7  
 Ramdhani A ..... (1):8–13  
 Rasyid B ..... (3):234–40  
 Redjeki S ..... (3):228–33  
 Reksodiputro MH ..... (3):246–51  
 Rengganis I ..... (3):241–5  
 Rinaldi I ..... (4):375–9  
 Rosalina ..... (3):300–8  
 Royhan A ..... (3):207–14  
 Rozaliyani A ..... (3):215–22  
 Rukmana A ..... (3):234–40  
 Saad FFA ..... (3):300–8  
 Sabahi MM ..... (1):28–34  
 Sabzehei MK ..... (1):28–34  
 Sadikin M ..... (1):14–20  
 Sadikin M ..... (2):196–202  
 Sadikin M ..... (3):207–14

- Saekhu M ..... (2):183–7  
 Safriadi F ..... (1):3–7  
 Santoso BI ..... (1):57–62  
 Sari OP ..... (4):370–4  
 Sari RM ..... (4):322–8  
 Saripan MI ..... (3):300–8  
 Sarsanti PAN ..... (1):14–20  
 Satari HI ..... (4):322–8  
 Sawitri DH ..... (2):196–202  
 Sayehmiri K ..... (1):35–9  
 Sekartini R ..... (2):167–73  
 Sekarutami SM ..... (2):141–5  
 Sekarutami SM ..... (4):391–5  
 Setiabudy R ..... (2):110–5  
 Setiabudy R ..... (3):215–22  
 Shadrina A ..... (1):40–6  
 Shokouhi M ..... (1):28–34  
 Siagian M ..... (2):154–61  
 Siahaan YMT ..... (3):276–9  
 Sinaga RSH ..... (2):141–5  
 Siregar B ..... (1):63–9  
 Siregar NC ..... (3):215–22  
 Siste K ..... (4):380–5  
 Sitohang IBS ..... (1):21–7  
 Sjarif DR ..... (1):70–6  
 Sjatha F ..... (3):234–40  
 Soebandrio A ..... (4):345–50  
 Soebono H ..... (1):77–81  
 Soejono CH ..... (4):358–64  
 Soetikno V ..... (3):292–9  
 Soetikno V ..... (4):309–10  
 Subiyanto AA ..... (2):174–82  
 Sudibyo ES ..... (4):370–4  
 Sudiro TM ..... (2):103–9  
 Suharno B ..... (1):92–7  
 Suharto W ..... (1):8–13  
 Sukeri NB ..... (2):162–6  
 Sulaeman ES ..... (2):174–82  
 Sumadi IWJ ..... (4):386–90  
 Sumbung NK ..... (3):292–9  
 Sundoro J ..... (4):322–8  
 Suppiah S ..... (3):300–8  
 Supriadi S ..... (1):92–7  
 Surya R ..... (1):57–62  
 Susanti NI ..... (4):338–44  
 Susilawati TN ..... (3):284–91  
 Susiyanti M ..... (3):215–22  
 Sutanto H ..... (4):358–64  
 Sutrisna B ..... (1):63–9  
 Suwardji K ..... (3):207–14  
 Suyatna FD ..... (3):207–14  
 Syafriyal ..... (4):322–8  
 Sylviningrum T ..... (4):370–4  
 Tambunan MP ..... (3):268–75  
 Tambunan T ..... (4):329–37  
 Tamtomo DK ..... (4):316–21  
 Tandian D ..... (2):183–7  
 Tandiyo DK ..... (4):316–21  
 Tantri AR ..... (4):311–5  
 Timan IS ..... (2):154–61  
 Timan IS ..... (4):338–44  
 Tjandrawidjaja G ..... (3):276–9  
 Topan H ..... (2):134–40  
 Trihono PP ..... (4):329–37  
 Tunan E ..... (3):300–8  
 Umbas R ..... (1):3–7  
 Utami RP ..... (3):292–9  
 Utari A ..... (2):116–22  
 Utari A ..... (2):123–8  
 Utari AP ..... (4):345–50  
 Uz Zaman A ..... (3):252–7  
 van Trotsenburg ASP ..... (4):396–401  
 Victor AA ..... (3):258–67  
 Wahid M ..... (1):21–7  
 Wangge G ..... (2):101–2  
 Wardhana AH ..... (2):196–202  
 Wardhani BWK ..... (2):110–5  
 Warli SM ..... (1):3–7  
 Wasyanto T ..... (2):129–33  
 Watanabe Y ..... (2):110–5  
 Waworuntu BM ..... (3):292–9  
 Werdhani RA ..... (1):8–13  
 Wibowo H ..... (2):196–202  
 Widjaja FF ..... (1):1–2  
 Widodo AD ..... (2):154–61  
 Widodo AD ..... (4):338–44  
 Widysanto A ..... (3):276–9  
 Wiguna T ..... (1):82–91  
 William A ..... (4):345–50  
 Winarni DRA ..... (1):77–81  
 Winarta W ..... (2):154–61  
 Windarti W ..... (4):396–401  
 Wiratnaya IGE ..... (4):386–90  
 Wisnu W ..... (1):47–56  
 Wiwie M ..... (1):40–6  
 Wulandari D ..... (1):63–9

- Yasmon A ..... (4):351–7  
 Yolanda S ..... (3):223–7  
 Yuliarti K ..... (1):70–6  
 Yunanto A ..... (2):146–53  
 Yuwana S ..... (4):365–9

### Subject Index

- acne vulgaris ..... (1):21–7  
 acupuncture therapy ..... (3):241–5  
 addictive ..... (4):380–5  
 adolescent ..... (2):123–8  
 adverse drug event ..... (4):322–8  
 aerobic exercise ..... (3):223–7  
 aerobic exercise ..... (3):228–33  
 Ahmed glaucoma valve ..... (3):258–67  
 aldehyde dehydrogenase 1A1 ..... (1):63–9  
 amphotericin B ..... (3):215–22  
 androgen receptor ..... (2):116–22  
 animal protein ..... (1):70–6  
 anterior cervical corpectomy ..... (2):183–7  
 antibiotics ..... (1):21–7  
 anxiety ..... (1):35–9  
*Aspergillus flavus* ..... (3):215–22  
 atrial natriuretic peptide ..... (2):129–33  
 BCRP ..... (2):110–5  
 behavior addiction ..... (1):82–91  
 bevacizumab ..... (3):258–67  
 biomarkers ..... (2):129–33  
 bladder cancer ..... (1):3–7  
 body fat ..... (2):154–61  
 bone graft ..... (1):92–7  
 bone scaffold ..... (1):92–7  
 bone substitute ..... (1):92–7  
 calcaneal spur ..... (4):316–21  
 calcium phosphate ..... (1):92–7  
 calf circumference ..... (4):365–9  
 cancer ..... (4):391–5  
 cancer stem cells ..... (1):63–9  
 carbonate apatite ..... (1):92–7  
 case report ..... (2):183–7  
 case study ..... (2):174–82  
 CATT/T. evansi ..... (2):196–202  
 CD133 antigen ..... (1):63–9  
 CD44 antigen ..... (1):63–9  
 cervical cancer ..... (2):141–5  
 chemotherapy response ..... (1):63–9  
 child ..... (4):329–37  
 children ..... (2):154–61  
 children ..... (2):167–73  
 children ..... (4):338–44  
 chronic kidney disease ..... (4):329–37  
 cisplatin ..... (3):292–9  
 colorectal cancer ..... (2):188–95  
 congenital hypothyroidism ..... (4):396–401  
 constipation ..... (4):345–50  
 continuous ambulatory peritoneal dialysis ..... (4):329–37  
 cranberry ..... (3):268–75  
 cytoglobin ..... (1):14–20  
 deficiency ..... (3):276–9  
 dementia ..... (3):300–8  
 dengue virus ..... (2):103–9  
 depression ..... (1):35–9  
 detrusor underactivity ..... (2):146–53  
 diabcare ..... (1):47–56  
 diabetes complication ..... (1):47–56  
 diabetes mellitus ..... (1):47–56  
 diabetes mellitus ..... (3):207–14  
 diagnosis ..... (3):284–91  
 disorders of sex development ..... (2):116–22  
 Ebola virus ..... (2):162–6  
 education ..... (4):380–5  
 endophthalmitis ..... (3):215–22  
 epithelial ovarian cancer ..... (1):63–9  
 estradiol ..... (1):40–6  
 etiology ..... (4):396–401  
 exocrine pancreatic insufficiency ..... (2):154–61  
 extracorporeal shockwave therapy ..... (4):316–21  
 fasting ..... (3):276–9  
 fatty tissue ..... (3):246–51  
 feces ..... (4):338–44  
 FELISA ..... (2):196–202  
 femoral fractures ..... (4):365–9  
 fertility ..... (1):35–9  
 fetal growth ..... (1):57–62  
 fibroblast growth factor receptor-3 ..... (1):3–7  
 finger ..... (4):311–5  
 functional status ..... (4):358–64  
 genetic marker ..... (2):188–95  
 genetic screening ..... (2):116–22  
 geographic information system ..... (2):174–82  
 GERD ..... (3):241–5  
 geriatrics ..... (3):300–8  
 geriatrics ..... (4):358–64  
 glycemic index ..... (2):123–8  
 growing-up milk ..... (1):70–6  
 health insurance ..... (4):358–64

- health risk assessment ..... (2):174–82  
 hemodialysis ..... (4):375–9  
 hepatitis C ..... (4):375–9  
 heterotopic ossification ..... (4):386–90  
 HIF-1 $\alpha$  ..... (1):14–20  
 HIF-2 $\alpha$  ..... (1):14–20  
 HLA-Cw6 ..... (4):370–4  
 HOMA-IR ..... (2):123–8  
 horseradish peroxidase ..... (2):103–9  
 hospital cost ..... (4):358–64  
 hospitalization ..... (4):358–64  
 human serum ..... (2):196–202  
 hypoglycemia ..... (1):47–56  
 hypospadias ..... (2):116–22  
 hypoxia ..... (1):14–20  
 hypoxia-inducible factor-1 $\alpha$  ..... (1):3–7  
 ileal intestinal villi ..... (1):8–13  
 immunogens ..... (3):234–40  
 immunotherapy ..... (4):391–5  
 incidence ..... (1):28–34  
 Indonesia ..... (4):345–50  
 infection ..... (3):284–91  
 infectious diseases ..... (2):174–82  
 infertility ..... (1):35–9  
 intellectual disability ..... (4):396–401  
 interleukin-6 ..... (3):241–5  
 internet ..... (4):380–5  
 internet addiction ..... (1):82–91  
 intertrochanteric fractures ..... (4):365–9  
 intraocular pressure ..... (3):258–67  
 Iran ..... (1):35–9  
 ischemia ..... (1):8–13  
 ischemia-reperfusion injury ..... (1):8–13  
 ischemic hypothermia ..... (1):8–13  
 ischemic preconditioning ..... (1):8–13  
 kidney ..... (3):292–9  
 kidney injury ..... (3):292–9  
 knowledge ..... (2):162–6  
 left ventricular dysfunction ..... (2):129–33  
 lepromatous leprosy ..... (1):77–81  
 lipids ..... (4):338–44  
 liver fibrosis ..... (4):375–9  
 low birth weight ..... (4):322–8  
 lower urinary tract symptoms ..... (2):146–53  
 macrophage ..... (1):14–20  
 malabsorption syndromes ..... (2):154–61  
 malabsorption syndromes ..... (4):338–44  
 Malaysia ..... (2):162–6  
 map ..... (2):174–82  
 menopausal symptoms ..... (1):40–6  
 mental disorders ..... (1):82–91  
 meta-analysis ..... (2):188–95  
 metabolic diseases ..... (2):188–95  
 mild cognitive impairment ..... (1):40–6  
 MnSOD ..... (2):141–5  
 molecular imaging ..... (3):300–8  
 MRP1 ..... (2):110–5  
 MRSA ..... (3):252–7  
 multiple pregnancy ..... (1):28–34  
*Mycobacterium leprae* ..... (4):351–7  
*Mycobacterium tuberculosis* ..... (3):234–40  
 NAFLD ..... (2):123–8  
 nasogastric ..... (4):311–5  
 neglected stent ..... (3):280–3  
 neovascularization ..... (3):258–67  
 neurocognitive disorder ..... (3):300–8  
 neuroligin 1 ..... (3):228–33  
 neurology ..... (3):300–8  
 neuroplasticity ..... (3):228–33  
 neurovascular compression ..... (2):134–40  
 NS-1 antigen ..... (2):103–9  
 obesity ..... (2):167–73  
 orthopedic biomaterials ..... (1):92–7  
 orthopedics ..... (3):252–7  
 overactive bladder ..... (2):146–53  
 oxidative stress ..... (3):292–9  
 pain assessment scale ..... (2):134–40  
 pancreatic elastase ..... (2):154–61  
 pancreatic function tests ..... (2):154–61  
 paucibacillary leprosy ..... (4):351–7  
 pediatrics ..... (4):386–90  
 peritonitis ..... (4):329–37  
 PGC-1 $\alpha$  ..... (1):14–20  
 P-glycoprotein ..... (2):110–5  
 photocoagulation ..... (3):258–67  
 physicians ..... (4):380–5  
 platelet-rich fibrin ..... (3):246–51  
 polyclonal antibody ..... (2):103–9  
 positron emission tomography ..... (3):300–8  
 predictive factors ..... (1):3–7  
 pregnancy outcome ..... (1):28–34  
 pregnancy-induced hypertension ..... (1):57–62  
 pregnant women ..... (4):322–8  
 premature birth ..... (4):322–8  
 preterm delivery ..... (1):57–62  
 prevalence ..... (3):252–7

- prevention .....(1):47–56  
 primary school .....(2):167–73  
 prophylaxis .....(3):268–75  
*Propionibacterium acnes* .....(1):21–7  
 psoriasis .....(4):370–4  
 psychiatry .....(4):380–5  
 quality of life .....(4):345–50  
 quality of life .....(4):396–401  
 radiation therapy .....(4):391–5  
 radiography .....(4):386–90  
 radioimmunotherapy .....(4):391–5  
 radiotherapy .....(2):141–5  
 radiotherapy .....(4):391–5  
 rats .....(3):207–14  
 real-time PCR .....(4):351–7  
 recombinant fusion proteins .....(3):234–40  
 reliability .....(4):345–50  
 reverse Sellick .....(4):311–5  
 risk factors .....(2):188–95  
*RpfB* .....(3):234–40  
 sleep disorders .....(2):167–73  
 small for gestational age .....(1):57–62  
 soybeans .....(3):207–14  
 spatial memory .....(3):223–7  
 spatial memory .....(3):228–33  
 spleen .....(3):234–40  
 squamous cell carcinoma .....(2):141–5  
*Staphylococcus aureus* .....(1):21–7  
*Staphylococcus aureus* .....(3):252–7  
*Staphylococcus epidermidis* .....(1):21–7  
 students .....(2):162–6  
 stunting .....(1):70–6  
 survival .....(4):329–37  
 survival of fat .....(3):246–51  
 systemic lupus erythematosus .....(1):77–81  
 telomerase reverse transcriptase .....(3):207–14  
 tetanus vaccine .....(4):322–8  
 thiamine .....(3):276–9  
 thigh .....(4):365–9  
 TMEPAI .....(2):110–5  
 toddler .....(1):70–6  
 treatment .....(4):396–401  
 treatment adherence .....(1):47–56  
 trigeminal neuralgia .....(2):134–40  
 triple-negative breast cancer cell .....(2):110–5  
*Trypanosoma evansi* .....(2):196–202  
 tuberculosis .....(3):284–91  
 tumor .....(4):391–5  
 tumor necrosis factor-alpha .....(2):129–33  
 ureteral catheters .....(3):280–3  
 ureterorenoscopy .....(3):280–3  
 urinary tract infection .....(3):268–75  
 urodynamics .....(2):146–53  
 uterine cervical neoplasms .....(2):141–5  
 validation studies .....(4):345–50  
 vascular endothelial growth factor .....(3):258–67  
 voiding disorder .....(2):146–53  
 voriconazole .....(3):215–22  
 Wernicke's encephalopathy .....(3):276–9  
 women .....(3):268–75

# **Medical Journal of Indonesia**

## **Instructions for Authors**

### **Submission**

The submitted manuscript should be addressed to Editor-in-chief of the Medical Journal of Indonesia. Manuscript must be submitted through online submission (<http://mji.ui.ac.id/journal/index.php/mji/about/submissions>) by registered users. You can easily register in the journal system. For further question contact us at [mji@ui.ac.id](mailto:mji@ui.ac.id).

### **General Principles**

As a basic requirement, all articles submitted to the Medical Journal of Indonesia must be original work, which has never been published previously and is submitted exclusively to the Medical Journal of Indonesia. They are written in the format of "Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals" (<http://www.icmje.org/>), which was updated in December 2018, and established by the International Committee of Medical Journal Editors (ICMJE). The Editorial Board reserves the right to edit all articles in aspects of style, format, and clarity. Authors may be required to revise their manuscripts for reasons of any aspect. Manuscripts with excessive errors in any aspect may be returned to authors for retyping or may be rejected. All manuscripts will be subjected to peer and editorial review.

We accept four types of articles: (1) original articles: **basic medical research, clinical research, or community research;** (2) **case report;** (3) **review article;** (4) **brief communication.** Basic medical research cover in vitro research or animal studies. Clinical research cover research done in human subjects. Community research cover research done in the community and are related to health policy. Case report cover interesting reports of some cases and case series that also provide some statistical analysis. Review articles include systematic and narrative review that have a novelty in medical field. Brief communication include preliminary reports and manuscripts that do not cover the above categories but are still related to and have an important impacts on medical research and health policy.

Authors must also supply:

1. ICMJE conflicts of interest statement form ([http://mji.ui.ac.id/journal/public/journals/1/coi\\_disclosure.pdf](http://mji.ui.ac.id/journal/public/journals/1/coi_disclosure.pdf)) (if there is any difficulties in accessing the form, you can directly visit <http://www.icmje.org/conflicts-of-interest/>),
2. copy of ethical approval (when needed), and
3. final checklist (<http://mji.ui.ac.id/journal/public/journals/1/FinalChecklist.pdf>) signed by all author(s).

A cover letter should be provided at the submission and addressed to Editor-in-chief of Medical Journal of Indonesia, which should include statement about all previous submissions of the manuscript and previous reports that might be regarded as redundant publication of the work. If the manuscript has been submitted previously to another journal, authors are encouraged

to provide previous comments along with the responses to accelerate the review process. Author(s) also have to mention the work whether it has been presented in a congress/conference/seminar.

Templates are available on <http://mji.ui.ac.id/journal/public/journals/1/template1.dot> for original articles and <http://mji.ui.ac.id/journal/public/journals/1/template2.dot> for case reports.

### **Study Ethics**

All submitted papers containing animal experiments and/or involving human subjects should have obtained approval from an independent ethics committee. The copy of approval should be provided to editorial office as mentioned above.

### **Publication Ethics**

The publisher of this journal is a member of Committee on Publication Ethics (COPE). This journal follows guidelines from COPE in facing all aspects of publication ethics and, in particular, how to handle cases of research and publication misconduct. All articles in this journal involving human subjects should respect principles of research ethics as described in Declaration of Helsinki and studies involving animals should obey the International Guiding Principles for Biomedical Research as developed by the Council for International Organization of Medical Sciences (CIOMS).

Medical Journal of Indonesia adapts COPE to meet high quality standard of ethics for publisher, editors, authors, and reviewers. As an essential issue, publication ethics needs to be explained clearly to improve the quality of the research worldwide. In this part, we explain the standard for editors, authors, and reviewers. In addition, publisher don't have right to interfere with the integrity of the contents and only support to publish in timely manner.

### **Clinical Trial Registration**

The authors are encouraged to register all clinical trials to the publicly accessible registration in any registry as recommended by ICMJE or integrated to WHO International Clinical Trials Registry Platform (ICTRP) (<https://www.who.int/ictrp/network/primary/en/>) or in ClinicalTrials.gov, which is a data provider to the WHO ICTRP. The trial registration number should be provided at the end of the abstract. The registration should be done prior to the conduct of the trial.

### **Structure and Language**

Articles will be published in US English, following American spelling. Articles in English that are linguistically inadequate may be rejected. Manuscripts should be written double-spaced in all parts of the manuscript using Times New Roman 12, with margin of 2.54 cm of all sides.

Articles must be submitted in the following structural order: title page and authorship, abstract, keywords, text, conflicts of interest, acknowledgments (if any), funding disclosure, references, tables, figures, and legends (if any).

## Title Page and Authorship

The **Title Page** should contain: title of the article (concise, no abbreviations, maximum 16 words); full names of authors (without academic title); author's affiliation [name(s) of department(s) and institution(s)]; disclaimers (if any); corresponding author's name, mailing address, telephone and fax numbers, and e-mail address of the author responsible for correspondence about the manuscript (institution specific address and e-mail address of the corresponding author will be published along with the article); source(s) of support in the form of grants, equipment, drugs, or all of these (if any); short running title [maximum 40 characters (letter and spaces)]; word counts [A word count for the text only (excluding abstract, acknowledgments, tables, figure legends, and references)]; number of figures and tables; and conflict of interest declaration for each author.

**Authorship** of articles should be limited to those who have contributed sufficiently to take public responsibility for the contents. This includes (a) conception and design, or analysis and interpretation of data, or both; (b) drafting the article or revising it critically for important intellectual content; (c) final approval of the version to be published; (d) and agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Contributors who meet fewer than all four criteria above should be listed in acknowledgment and the contributions should be specified. Corresponding authors should assure the permission of all acknowledged individuals written in the acknowledgment.

## Abstract and Keywords

The **abstract** should be prepared in English with a structured abstract maximum 250 words for biomedical, clinical, and community research articles; and unstructured maximum 150 words for case report, brief communication, and review article. They should be concise and precise with enough information, highlighting the points and importance of the article which contains: One or two sentences of background, purpose of study; methods (basic procedures, study subject selection, observational, and analytical methods); main findings or results; and principal conclusion. **Keywords** are limited to 3–6 words or short phrases that will allow proper and convenient indexing. They should be obtained from Medical Subject Headings (MeSH®) (<https://meshb.nlm.nih.gov/search>) thesaurus produced by National Library of Medicine.

## Main Text

The **text** should be structured as **introduction, methods, results, and discussion** (IMRAD). Methods should provide clarity about how, why, and when the study was done.

The methods section should include the statement of approval by local, regional, or national review board. It should also clearly describe the selection of the study's participants. Equipment used should be identified in methods by specifically giving the manufacturer's name and address in parentheses. Give references to established methods. Conclusion should be stated at last sentence in the discussion. Footnotes are not advisable; their contents should rather be incorporated into the text. Use only standard abbreviations; use of nonstandard abbreviations can be confusing to readers. Avoid abbreviations in the title of the manuscript. The spelled-out abbreviation followed by the abbreviation in parenthesis should be used on first mention unless the abbreviation is a standard unit of measurement. If a sentence begins with a number, it should be spelled out. Cite in numerical order every reference, figure, and table. Use Arabic numerals in superscript to cite references in National Library of Medicine style.

## Statistical Methods

All **statistical methods** used should be described in detail in the methods section of the manuscript. Avoid relying solely on statistical hypothesis testing, such as p values, which fail to convey important information about effect size and precision of estimates. Define statistical terms, abbreviations, and most symbols. Specify the computer software and version used.

## Conflicts of Interest

**Conflicts of interest** should be transparent as detail as possible as provided in the ICMJE form as a standardized authors' disclosures. Financial and personal relationships are easily identifiable that might bias or be seen to bias the work. Funding sources for the work should be described specifically with explanations of the role of those sources and the authors should declare that the supporting sources had no involvement in specific role. The authors should declare that the authors had access to all the study and the sponsors did not intervene the data or the work. Each author should submit a separate form from ICMJE.

## Acknowledgments

Personal **acknowledgments** should be limited to appropriate professionals who contributed to the paper, including technical help and financial or material support, also general support by a department chair-person.

## Funding sources

Funding sources for the work should be described specifically with explanations of the role of those sources and the authors should declare that the supporting sources had no involvement in specific role. It should be written separately and limited to the funding for the work. The role of the funder(s) need to be described whether they have role in the design; data collection, management, analysis and interpretation of the data; and preparation, review, an approval of the manuscript; or the decision to submit the manuscript for publication.

## Tables and Figures

Total number of Table and figures are advisably not to exceed 6 in number. **Tables** and its title should be presented in separate sheets. Tables should be numbered in Arabic numerals, captions should be brief, clearly indicating the purpose or content of each table. Provide a footnote to each table, identifying in alphabetical order all abbreviations used. Number tables consecutively in the order of their first citation in the text and supply a brief title for each. Do not use internal horizontal or vertical lines. Give each column a short or an abbreviated heading. Explain all nonstandard abbreviations and explanatory matters in footnotes, and for explanatory matters use the following symbols, in sequence: \*, †, ‡, §, ¶, \*\*, ††, ‡‡, §§, ¶¶, etc. Identify statistical measures of variations, such as standard deviation and standard error of the mean. Be sure that each table is cited in the text. If you use data from another published or unpublished source, obtain permission and acknowledge that source fully.

**Figures** should be either professionally drawn or photographed, and submitted in a format (JPEG or TIFF) in the following resolutions [gray-scale or color in RGB (red, green, blue mode) at least 300 dpi (dots per inch). For x-ray films, scans, and other diagnostic images, as well as pictures of pathology specimens or photomicrographs, send sharp, glossy, black-and-white or color photographic prints, usually 127 x 173 mm (5 x 7 inches). Write the word "top" on the back of each figure at the appropriate place. Figures should be made as self-explanatory as possible, titles and detailed explanations belong in the legends-not on the figures themselves. Photomicrographs should have internal scale markers. Symbols, arrows, or letters used in photomicrographs should contrast with the background. When symbols, arrows, numbers, or letters are used to identify parts of the illustrations, identify and explain each one clearly in the legend. Explain the internal scale and identify the method of staining in photomicrographs. Photographs of potentially identifiable people must be accompanied by written permission to use the photograph.

Tables and figures should be numbered consecutively according to the order in which they have been cited in the text. If a figure has been published previously, acknowledge the original source and submit written permission from the copyright holder to reproduce it. Permission is required irrespective of authorship or publisher except for documents in the public domain using license of CC BY SA. Color figures are allowed in special circumstances, provided that the author is willing to cover the cost of reproduction. If the original size of the figures is too large, you can provide us lower quality figures on submission and good quality figures after the acceptance of the manuscript.

## Units of Measurement

For measurements use both local and S.I. (System International) units. Measurements should be abbreviated (e.g. mm, kcal, etc.) in accordance with the Style Manual for Biological Sciences and using the metric system. Measurements of length, height, weight, and volume should be reported in appropriate scientific

units. Temperatures should be in degrees Celsius. Blood pressures should be in millimeters of mercury (mmHg). Drug concentrations may be reported in either SI or mass units, but the alternative should be provided in parentheses where appropriate.

## References

**References** are advisably not to exceed 25 in number but not less than 10, and should in general be limited to the last decade. Reference exceed than 25 may be accepted when it is necessary. References must be numbered in the order in which they are mentioned in the text. Use the style of the examples below, which are based on the International Committee of Medical Journal Editors (ICMJE) Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals: Sample References ([http://www.nlm.nih.gov/bsd/uniform\\_requirements.html](http://www.nlm.nih.gov/bsd/uniform_requirements.html)). The titles of journals should be abbreviated according to the style used for MEDLINE ([www.ncbi.nlm.nih.gov/nlmcatalog/journals](http://www.ncbi.nlm.nih.gov/nlmcatalog/journals)). Avoid using abstracts as references. Information from manuscripts submitted but not yet accepted should be cited in the text as "unpublished observations" with written permission from the source. Papers accepted but not yet published may be included as references; designate the journal and add "Forthcoming". Avoid citing "personal communication" unless it provides essential information not available publically, name the person and date of communication, obtain written permission and confirmation of accuracy from the source of personal communication. Authors is recommended to use reference management software, in writing the citations and references such as: Mendeley®, Zotero®, EndNote®, and Reference Manager®.

Here are some examples of the references:

### 1. Standard journal article

Up to six authors, list all the authors.

- Halpern SD, Ubel PA, Caplan AL. Solid-organ transplantation in HIV-infected patients. *N Engl J Med.* 2002 Jul 25;347(4):284-7.

More than six authors, list the first six authors, followed by et al.

- Rose ME, Huerbin MB, Melick J, Marion DW, Palmer AM, Schiding JK, et al. Regulation of interstitial excitatory amino acid concentrations after cortical contusion injury. *Brain Res.* 2002;935(1-2):40-6.

Optional addition of a database's unique identifier for the citation: [Edited 12 May 2009]

- Halpern SD, Ubel PA, Caplan AL. Solid-organ transplantation in HIV-infected patients. *N Engl J Med.* 2002 Jul 25;347(4):284-7. PubMed PMID: 12140307.
- Forooghian F, Yeh S, Faia LJ, Nussenblatt RB. Uveitic foveal atrophy: clinical features and associations. *Arch Ophthalmol.* 2009 Feb;127(2):179-86. PubMed PMID: 19204236; PubMed Central PMCID: PMC2653214.

Optional addition of a clinical trial registration number: [Added 12 May 2009]

- Trachtenberg F, Maserejian NN, Soncini JA, Hayes C, Tavares M. Does fluoride in compomers prevent future caries in children? *J Dent Res.* 2009 Mar;88(3):276-9. PubMed PMID:

19329464. ClinicalTrials.gov registration number: NCT00065988.

As an option, if a journal carries continuous pagination throughout a volume (as many medical journals do) the month and issue number may be omitted.

- Halpern SD, Ubel PA, Caplan AL. Solid-organ transplantation in HIV-infected patients. *N Engl J Med.* 2002;347:284-7.

## 2. Chapter in a book

Meltzer PS, Kallioniemi A, Trent JM. Chromosome alterations in human solid tumors. In: Vogelstein B, Kinzler KW, editors. *The genetic basis of human cancer.* New York: McGraw-Hill; 2002. p. 93–113.

## 3. Homepage/Web site [Edited 12 May 2009]

Cancer-Pain.org [Internet]. New York: Association of Cancer Online Resources, Inc.; c2000-01 [updated 2002 May 16; cited 2002 Jul 9]. Available from: <http://www.cancer-pain.org/>.

## Peer Review Process

The submitted manuscript will be checked by an editor whether it is suitable with our focus and scope or has a major methodological flaw in two weeks. A staff will check whether the requirements are complete in one week. Authors will be given two weeks after notification is sent to complete the incomplete requirements. Failure to complete will make the manuscript rejected without being reviewed. Every submitted manuscript which pass this step, will be checked by Similarity Check to identify any plagiarism. Then, an editor and an editorial assistant will be assigned to the manuscript. It will be reviewed by two reviewers with double-blind method. At least one of the reviewer is appointed from other institutions (national or international). The manuscript will be sent to the reviewers anonymously. Reviewers' comments are also sent anonymously to corresponding author to take the necessary actions and responses. The decision of the revised manuscript will be then evaluated by the editor and the final decision will be sent to the corresponding author. The accepted manuscript will be sent to Enago™ for language editing. Then, final approval is needed from the corresponding author before it is published in the upcoming issue.

## Copyright Notice

Authors who publish with Medical Journal of Indonesia agree to the following terms:

1. Authors retain copyright and grant Medical Journal of Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License (<http://creativecommons.org/licenses/by-nc/4.0/>) that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work's authorship and initial publication in Medical Journal of Indonesia.
2. Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Medical Journal of Indonesia.

## Publication Fee

This journal only charges the article publication fee for all manuscript types, without any submission fee. The publication fee is US\$ 300 for foreign authors and IDR 3,000,000,- for Indonesian authors. For each printed page that contains colored figure, you will be asked to pay US\$ 50 (IDR 500,000,-) each printed page more.

When the accepted manuscript has been proofread by the authors, Medical Journal of Indonesia office will send the invoice to the corresponding author and they need to complete the payment process before being published. To enhance the research in health programme, Medical Journal of Indonesia will cover the publication fee of authors from the countries that are included in group A and group B countries of HINARI by WHO. Waiver of payment is not only limited to those countries. All authors may ask a waive, and they need to send letter of waiver to editor-in-chief explaining the importance of the study and why author(s) need to be waived. The decision is made prior to the process of the review and it is the editors' privilege to approve or reject the request.

# **Medical Journal of Indonesia**

## **Final Checklist & Submission Form**

## Title of article:

Type:  Basic medical research  
 Clinical research

- Community research
- Case report

- Review article
- Brief communication

## **1. Manuscript Preparation**

The author(s) affirm that the material has not been previously published and that the author(s) have not transferred elsewhere any rights to the article. The author(s) have checked the manuscript to comply with the instructions for authors of Medical Journal of Indonesia and agreed to contribute for publication fee.

## 2. Informed Consent

The author(s) haven't suggested any personal information that may make the identity of the patient recognizable in any forms of description part, photograph or pedigree. When the photographs of the patient were essential and indispensable as scientific information, the author(s) have received the consent in writing form and have clearly stated it.

### **3. Human and Animal Right**

In case of experimenting on human, the author(s) have certified that the process of the research is in accordance with ethical standards of Helsinki declaration, domestic and foreign committees that preside over human experiment. If any doubts is raised whether the research was proceeded in accordance with the declaration, the author(s) would explain it. In case of experimenting on animals, the author(s) have certified that the author(s) had followed the domestic and foreign guideline related to experiment of animals in a laboratory.

## 4. Permission Approvals

The author(s) have received consent from the author or editor the picture or the table that was quoted from other journals or books. A portion or entire of the article hasn't been published on other journals nor contributed to other journals and under review.

## **5. Copyright Notice**

The author(s) undersigned hereby give Faculty of Medicine Universitas Indonesia as publisher the right of first publication of all published material and licensed under a Creative Commons Attribution-NonCommercial 4.0 International (<http://creativecommons.org/licenses/by-nc/4.0/>).

## **6. Disclosure of Conflict of Interest**

Author(s) of the journal have clarified everything that interest may arise such as work, research expenses, consultant expenses, and intellectual property on the document of ICMJE form disclosure of conflicts of interest.

Full Name:

Signature:

E-mail:

Date:



